Real-world cost effectiveness of first-line pembrolizumab for advanced melanoma: A population-based study by the Canadian Real-world Evidence Value for Cancer Drugs (CanREValue) Collaboration.

被引：0

作者：

Hanna, Timothy

Aktar, Suriya

Arciero, Vanessa

Liu, Ning

Chan, Kelvin K.

机构：

[1] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada

[2] ICES, Toronto, ON, Canada

[3] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada

[4] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 28期

基金：

加拿大健康研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：17 / 17

页数：1

共 50 条

[1] Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Chan, Kelvin
Nam, Seungree
Evans, Bill
de Oliveira, Claire
Chambers, Alexandra
Gavura, Scott
Hoch, Jeffrey
Mercer, Rebecca E.
Dai, Wei Fang
Beca, Jaclyn
Tadrous, Mina
Isaranuwatchai, Wanrudee
BMJ OPEN, 2020, 10 (01):
[2] Real-world cost-effectiveness of pertuzumab (P) with trastuzumab plus chemo (T plus Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.
Dai, Wei Fang
Beca, Jaclyn Marie
Nagamuthu, Chenthila
Liu, Ning
Trudeau, Maureen E.
Earle, Craig
De Oliveira, Claire
Chan, Kelvin K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
Parmar, Ambica
Dai, Wei Fang
Dionne, Francois
Geirnaert, Marc
Denburg, Avram
Ahuja, Tarry
Beca, Jaclyn
Bouchard, Sylvie
Chambers, Carole
Hunt, Melissa J.
Husereau, Don
Lungu, Elena
McDonald, Valerie
Mercer, Rebecca E.
Mitera, Gunita
Munoz, Caroline
Naipaul, Rohini
Peacock, Stuart
Potashnik, Tanya
Tadrous, Mina
Takhar, Pam
Taylor, Marianne
Trudeau, Maureen
Wasney, Danica
Gavura, Scott
Chan, Kelvin K. W.
CURRENT ONCOLOGY, 2023, 30 (04) : 3776 - 3786
[4] Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group
Dai, Wei Fang
de Oliveira, Claire
Blommaert, Scott
Pataky, Reka E.
Tran, David
Aurangzeb, Zeb
Kendell, Cynthia
Folkins, Chris
Somayaji, Chandy
Dowden, Jeff
Cheung, Winson
Strumpf, Erin
Beca, Jaclyn M.
McClure, Carol
Urquhart, Robin
McDonald, James Ted
Alvi, Riaz
Turner, Donna
Peacock, Stuart
Denburg, Avram
Mercer, Rebecca E.
Munoz, Caroline
Parmar, Ambica
Tadrous, Mina
Takhar, Pam
Chan, Kelvin K. W.
CURRENT ONCOLOGY, 2022, 29 (03) : 2046 - 2063
[5] First-line pembrolizumab for lung cancer in a Spanish real-world study.
Burgos, Amparo
Calleja, Teresa
Ibanez, Cristina
Maria Valencia, Carmen
Orallo, Claudia
Carlos Titos, Jose
Conde, David
Diaz, Sacramento
Matilla, Belen
Lizeaga, Garbine
Sanchez, Carmen
Marin Pozo, Juan Francisco
Jimenez, Silvia
Jimenez, Inmaculada
Diez, Raul
Garrido, Margarita
Larrosa, Maria
Jose Martinez, Maria
Moreno, Estela
Garcia Campelo, Rosario
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned
Evans, William K.
Takhar, Pam
McDonald, Valerie
Elias, Martine
Binder, Louise
Michaud, Stephanie
Tadrous, Mina
Munoz, Caroline
Chan, Kelvin K. W.
CURRENT ONCOLOGY, 2022, 29 (08) : 5616 - 5626
[7] Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study
van Zeijl, Michiel C. T.
Haanen, John B. A. G.
Wouters, Michel W. J. M.
de Wreede, Liesbeth C.
Jochems, Anouk
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen W.
Piersma, Djura
van Rijn, Rozemarijn S.
Suijkerbuijk, Karijn P. M.
ten Tije, Albert J.
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
van der Hoeven, Koos J. M.
van den Eertwegh, Alfons J. M.
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (08) : 256 - 264
[8] Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
Takhar, Pam
Geirnaert, Marc
Gavura, Scott
Beca, Jaclyn
Mercer, Rebecca E.
Denburg, Avram
Munoz, Caroline
Tadrous, Mina
Parmar, Ambica
Dionne, Francois
Boehm, Darryl
Chambers, Carole
Craig, Erica
Trudeau, Maureen
Cheung, Matthew C.
Houlihan, Joanne
Mcdonald, Valerie
Pechlivanoglou, Petros
Taylor, Marianne
Wasylenko, Eric
Wranik, Wieslawa Dominika
Chan, Kelvin K. W.
CURRENT ONCOLOGY, 2024, 31 (04) : 1876 - 1898
[9] Real-World Outcomes of First-Line Chemotherapy in Metastatic Pancreatic Cancer: A Nationwide Population-Based Study in Korea
Park, Chan Su
Park, Byung Kyu
Han, Joung-Ho
Lee, Kyong Joo
Son, Kang Ju
CANCERS, 2024, 16 (18)
[10] Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise
Dai, Wei Fang
Craig, Erica
Fraser, Brent
Chambers, Alex
Mai, Helen
Brown, M. Bryson
Earle, Craig C.
Evans, William K.
Geirnaert, Marc
Taylor, Marianne
Trudeau, Maureen
Sperber, Daniel
Beca, Jaclyn M.
Denburg, Avram
Mercer, Rebecca E.
Parmar, Ambica
Tadrous, Mina
Takhar, Pam
Chan, Kelvin K. W.
CURRENT ONCOLOGY, 2021, 28 (06) : 4645 - 4654

← 1 2 3 4 5 →